Clinical trials: Patients With Bipolar Disorders
Major Depression
Wake and Light Therapy to In-patients With Major Depression: Efficacy, Predictors and Patient Experiences
The objective of the study is to examine whether a combination of wake therapy, light therapy and sleep time stabilization as a supplement to standard treatment can reduce depressive symptoms in patients admitted at two…
- Trial name
- NCT02047968
- Testing
- wake therapy
- Where
- Denmark
- Volunteers
- 64 people
- Sponsor
- University of Aarhus
Diabetes Mellitus, Type 2, Severe Mental Disorder
Improving Diabetes Outcomes for People With Severe Mental Illness (SMI)
This study aims to identify the determinants of diabetes and to explore variation in diabetes outcomes for people with severe mental illness (schizophrenia, schizoaffective disorder and bipolar disorder) in order to develop…
- Trial name
- EMERALD (NCT03534921)
- Where
- United Kingdom
- Volunteers
- 46,564 people
- Sponsor
- University of York
Bipolar Disorder
Efficacy and Safety of Lu AA39959 in Patients With Bipolar Depression
This study will evaluate the efficacy and safety of Lu AA39959 in the treatment of depression in patients with bipolar disorder.
- Trial name
- NCT00771134
- Testing
- Lu AA39959, Quetiapine
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- H. Lundbeck A/S
Schizophrenia and Schizoaffective Disorder, Bipolar Disorder (BD)
Survey on the Reproductive and Child-Rearing Situations of Patients With Severe Mental Disorders
Severe mental disorders represent a major public health concern, imposing substantial disease burden and adversely affecting multiple dimensions of patients' lives, while also creating intergenerational impacts on their offspring…
- Trial name
- NCT07005245
- Where
- China
- Volunteers
- 77,145 people
- Sponsor
- Peking University
Bipolar Disorder Mania
Study to Evaluate the Efficacy and Safety of Aripiprazole Administered With Lithium or Valproate Over 12 Weeks in the Treatment of Mania in Bipolar I Disorder
The purpose of the study is to determine whether aripiprazole provides additional clinical benefit to patients with Bipolar I disorder when combined with lithium or valproate over 12 weeks.
- Trial name
- NCT00665366
- Testing
- Aripiprazole, Lithium, Valproate
- Where
- 73 sites in Austria, Czechia and 11 more
- Volunteers
- 493 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Insomnia, Bipolar Disorder
Efficacy of Suvorexant to Treat Insomnia Related to Bipolar Disorder
The purpose of this study is to evaluate the efficacy of suvorexant, added to existing medications, for treatment-resistant insomnia in individuals with bipolar disorder.
- Trial name
- NCT02527564
- Testing
- Suvorexant
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Stanford University
Schizophrenia, Psychotic Disorders
The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder
Olanzapine is currently marketed for the treatment of schizophrenia and acute manic episodes with bipolar 1 disorder. This Anti-obesity Agent is currently marketed for the management of obesity.
- Conditions
- Schizophrenia, Psychotic Disorders, Bipolar Disorder
- Trial name
- NCT00044187
- Testing
- Sibutramine
- Where
- 16 sites in United States
- Volunteers
- 130 people
- Sponsor
- Eli Lilly and Company
Atrial Fibrillation (Paroxysmal)
Pulsed Field Ablation With Concomitant Radiofrequency Cardioneuroablation in Patients With Paroxysmal Atrial Fibrillation
Pulsed-field ablation (PFA) is a novel, non-thermal method for the treatment of atrial fibrillation (AF). It uses short, high-voltage electrical pulses to selectively ablate cardiomyocytes.
- Trial name
- PFACNA-AF (NCT07171463)
- Testing
- Pulmonary Vein Isolation using Point-by-Point Bipolar Pulsed-Field Ablation, Selective Radiofrequency Ablation of the Superior Paraseptal Parasympathetic Ganglion
- Where
- Poland
- Volunteers
- 20 people
- Sponsor
- St. Joseph's Centre, Poland
Bipolar Disorder (BD)
Research on the Efficacy and Safety of Targeted Suprachiasmatic Nucleus Electrical Stimulation for Improving Metabolic Disorders in Patients With Stable Bipolar Disorder Comorbid With Obesity
This study aims to stabilize the patients with bipolar disorder (BD) comorbid with obesity in the stable phase by using temporal interference stimulation (TIS ) intervention.
- Trial name
- NCT07589647
- Testing
- Temporal Interference Stimulation
- Where
- China
- Volunteers
- 70 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
tDCS
tDCS(Transcranial Direct Current Stimulation) Efficacy in Bipolar Depression : RCT Study
The purpose of this study is to determine whether transcranial direct current stimulation (tDCS) is effective and safe in the treatment Bipolar depression. Randomized, double-blind Controlled Clinical Trial.
- Trial name
- NCT03974815
- Testing
- ACTIVE
- Where
- South Korea
- Volunteers
- 64 people
- Sponsor
- Seoul National University Hospital
Bipolar Affective Disorder, Currently in Remission, Bipolar Disorder I
Effect of Behavioral Intervention on Cannabinoid Receptors in BAD
The objective of this study is to determine whether the practice of a non-drug related intervention technique (behavioral modification technique consisting of a combination of breathing exercises, cold exposure and meditation)…
- Conditions
- Bipolar Affective Disorder, Currently in Remission, Bipolar Disorder I, Bipolar Disorder II
- Trial name
- WHM_BAD (NCT04168697)
- Testing
- Wim Hof method
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Wayne State University
Benign Prostatic Hypertrophy
Transurethral Vapor Enucleation Resection of the Prostate (TVERP), Bipolar TURis and HoLEP
To verify the safety and efficacy of the use of the plasma vaporisation button in Transurethral Vapor Enucleation and Resection of the prostate (TVERP) for treatment of Benign prostatic hypertrophy (BPH) patients with prostate…
- Trial name
- NCT04398420
- Testing
- TVERP, TURis, HoLEP
- Where
- 3 sites in China
- Volunteers
- 29 people
- Sponsor
- Olympus Surgical Technologies Europe
Bipolar Depression
Lumateperone Monotherapy for the Treatment of Bipolar Depression Conducted Globally
The study will evaluate the efficacy and safety of ITI-007 in a randomized, double-blind, parallel-group, placebo-controlled, multi-center study in patients diagnosed with Bipolar I or Bipolar II disorder having a major…
- Trial name
- NCT03249376
- Testing
- Lumateperone
- Where
- 47 sites in United States, Bulgaria and 4 more
- Volunteers
- 381 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Bipolar Disorder, Bipolar Depression
A Study To Investigate The Antidepressant Effect Of Lamotrigine In Patients With Bipolar Disorder Using Lithium
This is a study that, in the first 16 weeks, investigates whether lamotrigine versus placebo offers effect on depressive episodes for patients with bipolar disorder (also known as manic depressive disorder) who use lithium.
- Trial name
- NCT00224510
- Testing
- lamotrigine
- Where
- 31 sites in Netherlands, Spain
- Volunteers
- 120 people
- Sponsor
- GlaxoSmithKline
Affective Psychosis, Bipolar, Manic Disorder
Phase 3 /Seroquel SR Acute Mania Monotherapy - US
The purpose of this study is to determine the safety and efficacy of sustained-release quetiapine fumarate (Seroquel®) in the treatment of patients with Acute Bipolar Mania for 3 weeks.
- Conditions
- Affective Psychosis, Bipolar, Manic Disorder, Manic-Depressive Psychosis, Mania
- Trial name
- NCT00422123
- Testing
- Quetiapine fumarate (Seroquel) SR
- Where
- 51 sites in United States
- Volunteers
- 447 people
- Sponsor
- AstraZeneca
Acute Mania in Bipolar Disorder
Quetiapine Fumarate (Seroquel) as Mono-Therapy or Adjunct to Lithium in the Treatment of Patients With Acute Mania in Bipolar Disorder
To compare the efficacy and safety of quetiapine fumarate given as mono-therapy or adjunct therapy to lithium in the treatment of patients with acute mania in bipolar disorder.
- Trial name
- MANIA (NCT00672490)
- Testing
- Quetiapine Fumarate, Lithium
- Where
- 16 sites in China
- Volunteers
- 376 people
- Sponsor
- AstraZeneca
Bipolar Disorder；Major Depressive Disorder；Mood Disorders
Investigation on Risk Factors for Suicide Among Chinese Patients With Mood Disorders
Main research objective: Through questionnaire surveys, obtain the occurrence levels of self-harm/suicide behaviors, the status of acquired suicidal ability, and their correlations with self-harm/suicide behaviors among patients…
- Trial name
- NCT07281729
- Where
- 2 sites in China
- Volunteers
- 25,000 people
- Sponsor
- Shanghai Mental Health Center
Schizophrenia, Schizoaffective Disorder
The Antiatherogenic Properties of HDL in Psychiatric Patients With and Without Antipsychotic Therapy
Background: Among individuals with schizophrenia, there is an increased prevalence of obesity, dyslipidemia ,diabetes mellitus and related conditions such as cardiovascular disease.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
- Trial name
- NCT01215383
- Where
- Israel
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Ziv Hospital
Prostate Cancer
Biomarker Analysis of Castration-resistant Prostate Cancer Undergoing Bipolar Androgen Therapy
This is an open label phase II, single-arm, biomarker multi-institutional pilot study. Men with progressive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen deprivation therapy (ADT) and…
- Trial name
- PSMA-BAT (NCT04424654)
- Testing
- Testosterone cypionate
- Where
- 2 sites in Brazil
- Volunteers
- 20 people
- Sponsor
- Hospital Sirio-Libanes
Bipolar Disorder
Abilify in Bipolar Disorder for 6 Weeks Treatment Effectiveness
To demonstrate the efficacy and safety of co-administration of Abilify(aripiprazole) with Depakote(divalproate) in the acute phase of 6-week treatment of acute mania in patients with bipolar disorder.
- Trial name
- SMART-A (NCT00545142)
- Testing
- Abilify(Aripiprazole), Depakote(Divalproate)
- Where
- South Korea
- Volunteers
- 280 people
- Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.